Key facts
- This page summarizes Fairmount Funds Management LLC's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
- 8 reported transactions and 20 derivative rows are listed below.
- Accepted by SEC: 03 Sep 2026, 17:30.
Fairmount Funds Management LLC - 03 Sep 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)
- Reporting relationship
- Director
- Issuer ticker
- APGE
- Reported as of
- 03 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Sep 2026, 17:30:14 UTC
- Prior SEC filing
- 11 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fairmount Funds Management LLC filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 03 Sep 2026.
Change
- Previous filing in this sequence was filed on 11 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (4)
CIK 0001802528
Primary reporting owner
Fairmount Funds Management LLC
- Relationship
- Director
- Address
- 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
- Signature
- /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
- Signature date
- 03 Sep 2026
CIK 0001769651
Fairmount Healthcare Fund II L.P.
- Relationship
- Director
- Address
- 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
- Signature
- /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP
- Signature date
- 03 Sep 2026
CIK 0001830177
Kiselak Tomas
- Relationship
- Director
- Address
- 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
- Signature
- /s/ Tomas Kiselak
- Signature date
- 03 Sep 2026
CIK 0001663607
Harwin Peter Evan
- Relationship
- Director
- Address
- 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
- Signature
- /s/ Peter Harwin
- Signature date
- 03 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -340,855
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Footnotes
- F1, F2
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -340,855
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Footnotes
- F1, F2
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -340,855
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Footnotes
- F1, F2
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -340,855
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Footnotes
- F1, F2
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Peter Harwin
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Peter Harwin
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Peter Harwin
- Footnotes
- F1
APGE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -51,166
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Peter Harwin
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APGE
transaction
Derivative
Non-Voting Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -6,743,321
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
- 6,743,321
- Exercise price
- Footnotes
- F1, F2, F3
APGE
transaction
Derivative
Non-Voting Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -6,743,321
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
- 6,743,321
- Exercise price
- Footnotes
- F1, F2, F3
APGE
transaction
Derivative
Non-Voting Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -6,743,321
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
- 6,743,321
- Exercise price
- Footnotes
- F1, F2, F3
APGE
transaction
Derivative
Non-Voting Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -6,743,321
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
- 6,743,321
- Exercise price
- Footnotes
- F1, F2, F3
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,758
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 47,758
- Exercise price
- $17.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,758
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 47,758
- Exercise price
- $17.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,758
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 47,758
- Exercise price
- $17.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,758
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 47,758
- Exercise price
- $17.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,370
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 10,370
- Exercise price
- $43.85
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,370
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 10,370
- Exercise price
- $43.85
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,370
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 10,370
- Exercise price
- $43.85
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,370
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 10,370
- Exercise price
- $43.85
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,461
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 14,461
- Exercise price
- $41.66
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,461
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 14,461
- Exercise price
- $41.66
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,461
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 14,461
- Exercise price
- $41.66
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,461
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 14,461
- Exercise price
- $41.66
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,657
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 7,657
- Exercise price
- $85.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,657
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 7,657
- Exercise price
- $85.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,657
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 7,657
- Exercise price
- $85.00
- Footnotes
- F4, F5, F6
APGE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,657
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Sep 2026
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
- 7,657
- Exercise price
- $85.00
- Footnotes
- F4, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Fairmount Funds Management LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration").
Footnote F2
Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F3
The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%.
Footnote F4
As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger.
Footnote F5
Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
Footnote F6
Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
SEC remarks
Fairmount and Fairmount Healthcare Fund II LP may each have been deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak served on the board of directors of the Issuer and is also a Managing Member of Fairmount.